Literature DB >> 7256085

An epidemiologic approach to pneumococcal disease.

I D Riley, R M Douglas.   

Abstract

In many countries of the developing world, pneumonia remains a leading cause of morbidity and premature mortality. In their quest for effective control measures not dependent on the socioeconomic changes in Western societies that have paralleled a reduction in mortality from pneumonia, these poorer countries are looking towards modern antibiotic therapy and pneumococcal vaccines as short-term approaches to the problem. This paper summarizes information about the response of human populations to Streptococcus pneumoniae with particular reference to the author's experience in Papua New Guinea, where penicillin resistance is an increasing problem and where pneumococcal vaccines have been shown in field trials to reduce mortality from respiratory disease among both adults and children. In each developing country, basic epidemiologic data are needed to assist in choosing the best available combination of strategies for control of disease due to S. pneumoniae. Our current understanding of the determinants of pneumococcal carriage and pneumococcal disease is still inadequate, however, and there is need for studies of the interaction of the pneumococcus and its host at the mucosal surface to better understand the differences in the behavior observed for the various serotypes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7256085     DOI: 10.1093/clinids/3.2.233

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  12 in total

Review 1.  Streptococcus pneumoniae.

Authors:  J R Catterall
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

Review 2.  Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review.

Authors:  Marinos C Makris; Konstantinos A Polyzos; Michael N Mavros; Stavros Athanasiou; Petros I Rafailidis; Matthew E Falagas
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

3.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

4.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

5.  Evaluation of sampling sites for detection of upper respiratory tract carriage of Streptococcus pneumoniae and Haemophilus influenzae among healthy Filipino infants.

Authors:  M R Capeding; H Nohynek; L T Sombrero; L G Pascual; E S Sunico; G A Esparar; E Esko; M Leinonen; P Ruutu
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

Review 6.  Antimicrobial resistance in Streptococcus pneumoniae: a growing universal concern.

Authors:  S S Hussein; A M Shibl; H M Bahakem; M M Sofan
Journal:  J Natl Med Assoc       Date:  1989-09       Impact factor: 1.798

7.  Comparison of four different sampling methods for detecting pharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children.

Authors:  S Rapola; E Salo; P Kiiski; M Leinonen; A K Takala
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

8.  Determination of antibodies to pneumococcal C polysaccharide in patients with community-acquired pneumonia.

Authors:  H Holmberg; A Krook; A M Sjögren
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

9.  Isolation and characterization of circulating immune complexes from patients with pneumococcal pneumonia.

Authors:  M A Mellencamp; L C Preheim; T L McDonald
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

Review 10.  Treatment of severe infections caused by penicillin-resistant pneumococci. Role of third generation cephalosporins.

Authors:  E Rubinstein; B Rubinovitch
Journal:  Infection       Date:  1994       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.